Literature DB >> 14610145

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale.

G Cavaletti1, G Bogliun, L Marzorati, A Zincone, M Piatti, N Colombo, G Parma, A Lissoni, F Fei, S Cundari, C Zanna.   

Abstract

The authors compared clinically based neurotoxicity scales with the Total Neuropathy Scale, with the aim of improving the grading of the severity of chemotherapy-induced peripheral neuropathy (CIPN). The severity of CIPN was evaluated in a series of 60 women treated with cisplatin- and paclitaxel-based chemotherapy. A reduced version of TNS (TNSr) was also compared. The authors concluded that the TNS and TNSr can be used to assess the severity of CIPN effectively, and the results of this evaluation can be reliably correlated with the oncologic grading of sensory peripheral neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610145     DOI: 10.1212/01.wnl.0000092015.03923.19

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  58 in total

1.  Evaluation of multiple neurotoxic outcomes in cancer chemotherapy.

Authors:  Bernard Weiss
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

2.  Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).

Authors:  Jacobien M Kieffer; Tjeerd J Postma; Lonneke van de Poll-Franse; Floortje Mols; Jan J Heimans; Guido Cavaletti; Neil K Aaronson
Journal:  Qual Life Res       Date:  2017-06-20       Impact factor: 4.147

Review 3.  A framework for assessment in oncology rehabilitation.

Authors:  Laura S Gilchrist; Mary Lou Galantino; Meredith Wampler; Victoria G Marchese; G Stephen Morris; Kirsten K Ness
Journal:  Phys Ther       Date:  2009-01-15

4.  Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.

Authors:  Akinbode Egbelakin; Michael J Ferguson; Emily A MacGill; Amalia S Lehmann; Ariel R Topletz; Sara K Quinney; Lang Li; Kevin C McCammack; Stephen D Hall; Jamie L Renbarger
Journal:  Pediatr Blood Cancer       Date:  2010-11-11       Impact factor: 3.167

5.  Longitudinal assessment of oxaliplatin-induced neuropathy.

Authors:  A Z Burakgazi; W Messersmith; D Vaidya; P Hauer; A Hoke; Michael Polydefkis
Journal:  Neurology       Date:  2011-08-24       Impact factor: 9.910

Review 6.  Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith
Journal:  Semin Oncol Nurs       Date:  2019-04-30       Impact factor: 2.315

7.  Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia.

Authors:  Sindhu Ramchandren; Marcia Leonard; Rajen J Mody; Janet E Donohue; Judith Moyer; Raymond Hutchinson; James G Gurney
Journal:  J Peripher Nerv Syst       Date:  2009-09       Impact factor: 3.494

8.  Occurrence of neuropathies in patients with severe heart failure before and after heart transplantation.

Authors:  Sergio Bagnato; Chiara Minà; Antonino Sant'Angelo; Cristina Boccagni; Caterina Prestandrea; Alessandra Caronia; Francesco Clemenza; Giuseppe Galardi
Journal:  Neurol Sci       Date:  2015-11-14       Impact factor: 3.307

9.  Development of a novel location-based assessment of sensory symptoms in cancer patients: preliminary reliability and validity assessment.

Authors:  Adam R Burkey; Peter A Kanetsky
Journal:  J Pain Symptom Manage       Date:  2008-12-06       Impact factor: 3.612

10.  CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.

Authors:  Jodi L Skiles; ChienWei Chiang; Claire H Li; Steve Martin; Ellen L Smith; Gilbert Olbara; David R Jones; Terry A Vik; Saskia Mostert; Floor Abbink; Gertjan J Kaspers; Lang Li; Festus Njuguna; Tammy J Sajdyk; Jamie L Renbarger
Journal:  Pediatr Blood Cancer       Date:  2017-11-08       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.